Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

J Clin Oncol. 2018 May 1;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394. Epub 2018 Jan 18.

Abstract

Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. Results The literature search identified 222 relevant studies to inform the evidence base for this guideline. Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma. Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki .

Publication types

  • Practice Guideline
  • Research Support, N.I.H., Intramural

MeSH terms

  • Combined Modality Therapy
  • Evidence-Based Medicine
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Mesothelioma / diagnosis*
  • Mesothelioma / pathology
  • Mesothelioma / therapy*
  • Neoplasm Staging
  • Pleural Neoplasms / diagnosis*
  • Pleural Neoplasms / pathology
  • Pleural Neoplasms / therapy*
  • Quality of Life
  • Survival Rate

Supplementary concepts

  • Mesothelioma, Malignant